Skip to main content
TipRanks
Go Ultimate75% OFF

Veradermics, Incorporated (MANE) Stock Price & Analysis

91 Followers

MANE Stock Chart & Stats

$129.66-$5.63(-4.16%)
At close: 4:00 PM EST
$100$125$150Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$128.24 - $136.97
52-Week Range
$32.00 - $156.63
Previous Close
$135.29
Volume
N/A
Average Volume (3M)
832.34K
Market Cap
$5.47B
Enterprise Value
$4.32B
Total Cash (Recent Filing)
$798.35M
Total Debt (Recent Filing)
$668.00K
Price to Earnings (P/E)
―
Beta
0.19
Next Earnings
Apr 05, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Clinical Validation

Positive results across two registration-directed studies provide meaningful clinical validation for VDPHL01. Efficacy, patient-reported benefits, and favorable safety in more than 1,000 participants strengthen the program’s late-stage positioning and could support future regulatory and commercial progress.

Clinical Safety And Durability

Twelve-month data add evidence that treatment benefits can persist beyond the initial evaluation period, while the reported tolerability profile reduces a key development risk. This combination supports continued advancement of VDPHL01 and may improve its potential treatment value if approved.

Strong Reported Cash Position

A reported $798.4 million liquidity balance provides substantial resources for continued clinical development and preparations for a potential launch. This financial cushion can extend operating capacity and reduce the immediate need to raise external capital while the late-stage program advances.

Bears Say

Pre-commercial Business Model

The absence of revenue means the company has not yet demonstrated commercial demand or product economics. Widening losses also show that substantial spending is required before potential approval and launch, leaving results dependent on successful clinical and regulatory execution.

Accelerating Cash Burn

Rapidly increasing operating cash outflows indicate that the business is not self-funding while development activity expands. Continued negative free cash flow can consume liquidity over time and may require additional financing, creating dilution or funding pressure before commercialization.

Deeply Negative Equity

The swing to deeply negative equity represents a major deterioration in net worth and weakens financial flexibility. Although reported debt was minimal, the negative capital position increases dependence on external funding and leaves less balance-sheet capacity to absorb setbacks or delays.

Veradermics, Incorporated News

MANE FAQ

What was Veradermics, Incorporated’s price range in the past 12 months?
Veradermics, Incorporated lowest stock price was $32.00 and its highest was $156.63 in the past 12 months.
What is Veradermics, Incorporated’s market cap?
Veradermics, Incorporated’s market cap is $5.47B.
When is Veradermics, Incorporated’s upcoming earnings report date?
Veradermics, Incorporated’s next earnings report is estimated for Apr 05, 2027 (not yet confirmed), which is in 140 days.
How were Veradermics, Incorporated’s earnings last quarter?
Veradermics, Incorporated released its earnings results on Nov 10, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.562 by $0.062.
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate is -0.61.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 42,195,473 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Veradermics, Incorporated reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.562. Following the earnings report the stock price went up 3.119%.
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Hedge funds hold Veradermics, Incorporated shares: the largest hedge-fund position in Veradermics, Incorporated is 72,326,746 shares, and hedge funds increased their holdings by 2.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology